| Bioactivity | CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and C, respectively. | ||||||||||||
| Invitro | CCT 137690 displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma (GI50=0.30 μM) and A2780 ovarian cancer cell line (GI50=0.14 μM). CCT 137690 inhibits in vitro phosphorylation of histone H3. CCT 137690 is a moderate inhibitor of the hERG ion-channel (IC50=3.0 μM)[1]. CCT137690 efficiently inhibits histone H3 and TACC3 phosphorylation (Aurora B and Aurora A substrates, respectively) in HCT116 and HeLa cells. Continuous exposure of tumour cells to the inhibitor causes multipolar spindle formation, chromosome misalignment, polyploidy and apoptosis[2]. | ||||||||||||
| Name | CCT 137690 | ||||||||||||
| CAS | 1095382-05-0 | ||||||||||||
| Formula | C26H31BrN8O | ||||||||||||
| Molar Mass | 551.48 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
CCT 137690
CAS: 1095382-05-0 F: C26H31BrN8O W: 551.48
CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.